Screener
Cytokinetics CYTK Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Net loss | $(404,793) | $(295,746) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | 38,993 | 27,311 |
| Stock-based compensation expense | 66,105 | 51,084 |
| Non-cash lease expense | 3,210 | 2,566 |
| Depreciation of property and equipment | 7,009 | 4,585 |
| Change in fair value of derivative liabilities | (400) | (2,600) |
| Change in fair value of liabilities related to RPI Transactions | (800) | 10,700 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's stock-based comp?
- Cytokinetics (CYTK) reported stock-based comp of $35.71M in Q2 2026.
- How has Cytokinetics's stock-based comp changed year-over-year?
- Cytokinetics's stock-based comp increased by 29.7% year-over-year, from $27.54M to $35.71M.
- What is the long-term trend for Cytokinetics's stock-based comp?
- Over 4 years (2021 to 2025), Cytokinetics's stock-based comp has grown at a 43.0% compound annual growth rate (CAGR), from $26.83M to $112.29M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Cytokinetics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude